CTIS2024-515579-36-00进行中（未招募）1 期
Hydroxychloroquine treatment for Recurrent Pregnancy Loss: a randomized double-blind placebo-controlled trial
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 186
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •= 4 confirmed consecutive pregnancy losses prior to gestational age 22+0 in women with unexplained recurrent pregnancy loss (RPL), = 3 confirmed consecutive pregnancy losses prior to gestational age 22+0 in women with unexplained RPL with minimum one second trimester loss
排除标准
- •Age < 18 years or > 40 years, Previous HCQ treatment in relation to conceive, > 1 previous live birth., Previous participation in current study., Prominent uterine abnormalities detected by hysterosalpingography/hysteroscopy or hydrosonography, Known prominent chromosome abnormalities for the couple trying to conceive, A menstrual cycle < 23 days or > 35 days if the pregnancy is conceived naturally. If the woman received fertility treatment the menstrual cycle has no consequence., Detection of positive lupus-anticoagulant or positive IgG/IgM for anticardiolipin-antibodies (=10 GPL kU/l, measured at the same laboratories at the Capital Region of Denmark) or plasma homocysteine =25 microgram/l by repeated measurements 12 weeks apart before the pregnancy., Positive HIV test or test indicating chronic hepatitis B or C., Psoriasis, retinopathic or serious hearing deficiency (contraindication for treatment with HCQ), Current chronic disease implicating a constant consumption of immunomodulatory medicine or medicine potentially harmful to the pregnancy/embryo, Hgb = 6.5 mmol/L, leucocytes < 3.5 E9/L, thrombocytes < 145 E9/L by the time of inclusion
研究者
相似试验
Unknown
1 期
Hydroxychloroquine in Unexplained Recurrent Pregnancy LossRecurrent Pregnancy LossNCT05237843Ain Shams University70
进行中（未招募）
1 期
Plaquenil treatment of recurrent precnancy losses – a randomized, placebo controlled studyRecurrent pregnancy losses. Women with >3 subsequent pregnancy losses or 3 pregnancy losses of which one was a 2. trimester loss.MedDRA version: 19.1Level: LLTClassification code 10072314Term: Pregnancy lossSystem Organ Class: 100000004868EUCTR2016-004981-24-DKHenriette Svarre Nielsen186
进行中（未招募）
不适用
Efficacy of the treatment with hydroxychloroquine in non responders HIV-infected HAART-treated patients - NDHIV infection (immunological nonresponders).MedDRA version: 9.1Level: LLTClassification code 10008922EUCTR2009-012499-28-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)40
进行中（未招募）
1 期
Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)Profliaxis of SARS-CoV-2 infectionMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862EUCTR2020-001441-39-ITIVERSITY OF OXFORD40,000
进行中（未招募）
1 期
Chloroquine/ hydroxychloroquine prevention of COVID-19 (COPCOV)EUCTR2020-001441-39-GBniversity of Oxford10,000